July 25, 2024 11:24 AM EDT
News Briefing

Gal­der­ma de­pri­or­i­tizes study for IL-31 drug; UCB stops work in rare en­cephali­tis

ENDPOINTS

Plus, news about Gly­coMimet­ics and In­di­v­ior:

Gal­der­ma stops plans to de­vel­op nemolizum­ab in Phase 2: The Swiss der­ma­tol­ogy com­pa­ny said it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times